These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 23990664)
1. New insights into von Hippel-Lindau function highlighted by investigation of the trichloroethylene-induced p.P81S hotspot mutation. Neckers L; Ricketts CJ; Marston Linehan W J Natl Cancer Inst; 2013 Sep; 105(18):1339-40. PubMed ID: 23990664 [No Abstract] [Full Text] [Related]
2. Pleiotropic effects of the trichloroethylene-associated P81S VHL mutation on metabolism, apoptosis, and ATM-mediated DNA damage response. Desimone MC; Rathmell WK; Threadgill DW J Natl Cancer Inst; 2013 Sep; 105(18):1355-64. PubMed ID: 23990666 [TBL] [Abstract][Full Text] [Related]
3. Hypoxia upregulates von Hippel-Lindau tumor-suppressor protein through RhoA-dependent activity in renal cell carcinoma. Turcotte S; Desrosiers RR; Beliveau R Am J Physiol Renal Physiol; 2004 Feb; 286(2):F338-48. PubMed ID: 14583436 [TBL] [Abstract][Full Text] [Related]
4. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720 [TBL] [Abstract][Full Text] [Related]
5. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway. Blancher C; Moore JW; Robertson N; Harris AL Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776 [TBL] [Abstract][Full Text] [Related]
6. p53 stabilization and transactivation by a von Hippel-Lindau protein. Roe JS; Kim H; Lee SM; Kim ST; Cho EJ; Youn HD Mol Cell; 2006 May; 22(3):395-405. PubMed ID: 16678111 [TBL] [Abstract][Full Text] [Related]
7. The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis. Barry RE; Krek W Trends Mol Med; 2004 Sep; 10(9):466-72. PubMed ID: 15350900 [No Abstract] [Full Text] [Related]
8. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations. Rathmell WK; Hickey MM; Bezman NA; Chmielecki CA; Carraway NC; Simon MC Cancer Res; 2004 Dec; 64(23):8595-603. PubMed ID: 15574766 [TBL] [Abstract][Full Text] [Related]
10. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Wykoff CC; Pugh CW; Maxwell PH; Harris AL; Ratcliffe PJ Oncogene; 2000 Dec; 19(54):6297-305. PubMed ID: 11175344 [TBL] [Abstract][Full Text] [Related]
11. Targeting of the VHL-hypoxia-inducible factor-hypoxia-induced gene pathway for renal cell carcinoma therapy. Sosman JA J Am Soc Nephrol; 2003 Nov; 14(11):2695-702. PubMed ID: 14569078 [TBL] [Abstract][Full Text] [Related]
12. Role of exon 2-encoded beta -domain of the von Hippel-Lindau tumor suppressor protein. Bonicalzi ME; Groulx I; de Paulsen N ; Lee S J Biol Chem; 2001 Jan; 276(2):1407-16. PubMed ID: 11024059 [TBL] [Abstract][Full Text] [Related]
13. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Turner KJ; Moore JW; Jones A; Taylor CF; Cuthbert-Heavens D; Han C; Leek RD; Gatter KC; Maxwell PH; Ratcliffe PJ; Cranston D; Harris AL Cancer Res; 2002 May; 62(10):2957-61. PubMed ID: 12019178 [TBL] [Abstract][Full Text] [Related]
14. Hypoxia and cell cycle regulation of the von Hippel-Lindau tumor suppressor. Liu W; Xin H; Eckert DT; Brown JA; Gnarra JR Oncogene; 2011 Jan; 30(1):21-31. PubMed ID: 20802534 [TBL] [Abstract][Full Text] [Related]
15. The von Hippel-Lindau tumor suppressor complex and regulation of hypoxia-inducible transcription. Conaway RC; Conaway JW Adv Cancer Res; 2002; 85():1-12. PubMed ID: 12374282 [No Abstract] [Full Text] [Related]
16. Expression of HIF-1 and ubiquitin in conventional renal cell carcinoma: relationship to mutations of the von Hippel-Lindau tumor suppressor gene. Hughson MD; He Z; Liu S; Coleman J; Shingleton WB Cancer Genet Cytogenet; 2003 Jun; 143(2):145-53. PubMed ID: 12781449 [TBL] [Abstract][Full Text] [Related]
17. Loss of the von Hippel Lindau tumor suppressor disrupts iron homeostasis in renal carcinoma cells. Alberghini A; Recalcati S; Tacchini L; Santambrogio P; Campanella A; Cairo G J Biol Chem; 2005 Aug; 280(34):30120-8. PubMed ID: 15985433 [TBL] [Abstract][Full Text] [Related]
18. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene]. Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350 [TBL] [Abstract][Full Text] [Related]
19. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Clifford SC; Cockman ME; Smallwood AC; Mole DR; Woodward ER; Maxwell PH; Ratcliffe PJ; Maher ER Hum Mol Genet; 2001 May; 10(10):1029-38. PubMed ID: 11331613 [TBL] [Abstract][Full Text] [Related]
20. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Wiesener MS; Münchenhagen PM; Berger I; Morgan NV; Roigas J; Schwiertz A; Jürgensen JS; Gruber G; Maxwell PH; Löning SA; Frei U; Maher ER; Gröne HJ; Eckardt KU Cancer Res; 2001 Jul; 61(13):5215-22. PubMed ID: 11431362 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]